OrbiMed, a leading global healthcare investment firm, has successfully raised more than $4.3 billion in commitments for its newest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V, and OrbiMed Royalty & Credit Opportunities IV.
These funds maintain OrbiMed’s tradition of investing on a global scale, ranging from seed stage investments in start-ups they incubate to growth capital ventures. OrbiMed provides bespoke financing solutions to its portfolio companies, encompassing equity, credit, and royalty-based financing. Their investment focus is centered on pioneering and growth-centric opportunities within healthcare sub-sectors such as biopharmaceuticals, medical devices, diagnostics, and tech-driven healthcare services.
Led by 21 partners and a robust team of over 130 professionals globally, OrbiMed’s expertise spans company incubation, strategy, operations, and finance, across major healthcare hubs in North America, Europe, and Asia.
A diverse group of investors, including medical institutions, university endowments, foundations, and more, have backed these funds. Carter Neild, Managing Partner at OrbiMed, expressed gratitude for the unwavering support from their long-standing partners.
BusinessNewsAsia